Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. IGC Pharma Inc. (IGC) Message Board

Scientific Review Highlights Stigma Directed at Pe

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 436
(Total Views: 219)
Posted On: 01/10/2023 4:54:43 PM
Avatar
Posted By: NetworkNewsWire
Scientific Review Highlights Stigma Directed at People Living with Chronic Pain

The International Association for the Study of Pain estimates that 20% of people worldwide live with chronic pain, with low- and middle-income countries reporting a higher chronic pain prevalence of around 33%. A recent scientific review by researchers from the Sapienza University of Rome has now revealed that chronic pain sufferers are increasingly becoming victims of stigma.

Stigma is defined by the World Health Organization (WHO) as a mark of disgrace, shame or disapproval that results in discrimination and exclusion from the community. When patients suffer from stigmatized conditions such as HIV/AIDS, obesity, and chronic pain, they are much less likely to seek medical treatment. Furthermore, outcomes for patients with stigmatized conditions tend to be worse compared to nonstigmatized conditions, even when they seek treatment.

In most cases, people experience chronic pain due to an injury or medical condition, with joint pain from either advanced age, infection or injury being the most common cause of chronic pain in America.

Johns Hopkins School of Medicine assistant professor of anesthesiology and critical care medicine Tina Doshi, stated that society “really devalues” individuals with chronic pain.

The Sapienza University of Rome researchers outlined several factors that play a significant role in the stigmatization of chronic pain. For starters, the absence of tissue damage or solid medical evidence to explain the cause of pain often leads to the stigmatization of chronic pain patients. Furthermore, the subjectivity and invisibility of chronic pain mean that some people may downplay the severity of a patient’s chronic pain, especially if they aren’t injured or suffering from a medical condition.

The researchers found that chronic pain seeps into every facet of life, and chronic pain patients often feel stigma at work, home and in most social settings as the people they regularly interact with simply do not know what it is like to live with chronic pain.

Such chronic pain stigmatization can lead to poor workplace relationships at the office, especially when chronic pain forces an individual to call in sick regularly. According to the researchers, migraines are among the most common causes of missed work in people aged 50 and below and are also one of the most stigmatized medical conditions.

On the other hand, employees who chose to go to work despite being in pain were more likely to have reduced productivity and a higher chance of burnout. The review revealed that this stigma is also present in medical settings, with clinicians often underassessing patient pain levels and undertreating their pain.

For some patients, this stigma often leads to social withdrawal, insomnia, reduced self-esteem and even the development of depression, with chronic pain sufferers being two times more likely to die from suicide. The researchers noted that physicians should take complaints of pain seriously and ensure they provide the necessary treatment to chronic pain patients.

The race to make better chronic pain treatments is on, and entities such as India Globalization Capital Inc. (NYSE America: IGC) are making headway that could bring cannabinoids to the forefront of hospital-based pain management.

NOTE TO INVESTORS: The latest news and updates relating to India Globalization Capital Inc. (NYSE American: IGC) are available in the company’s newsroom at https://ibn.fm/IGC

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




IGC Pharma Inc. (IGC) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us